Cardioprotection in the Modern Era of Cancer ChemotherapyGodishala, Anuradha, MD; Yang, Shu, MD; Asnani, Aarti, MDCardiology in Review: May/June 2018 - Volume 26 - Issue 3 - p 113–121 doi: 10.1097/CRD.0000000000000194 Review Articles Buy Abstract Author InformationAuthors Article MetricsMetrics The current arsenal of cancer chemotherapy is broad and rapidly expanding and includes conventional cytotoxic agents and targeted and immune-based therapies. As cancer survival rates have improved, the acute and latent cardiotoxicities of chemotherapy have emerged as important contributors to morbidity and mortality in cancer survivors. All chemotherapeutic agents have the potential for cardiac complications, with manifestations ranging from subclinical left ventricular dysfunction and asymptomatic QT prolongation, to congestive heart failure, myocardial ischemia, myocarditis, arrhythmia, and sudden cardiac death. Efforts are ongoing to identify patients at high risk of cardiac complications and to develop evidence-based approaches to cardioprotection. In this review, we describe antitumor agents commonly associated with cardiotoxicity, with a focus on risk assessment, surveillance strategies, and pharmacologic and nonpharmacologic interventions aimed at preventing and mitigating chemotherapy-induced myocardial dysfunction. From the Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA. Disclosure: The authors declare no conflict of interest. Correspondence: Aarti Asnani, MD, Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, CLS-911, 3 Blackfan Circle, Boston, MA 02115. E-mail: email@example.com Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.